

## Original Article

***Phellinus linteus* Extract Augments the Immune Response in Mitomycin C-Induced Immunodeficient Mice**Shintaro Matsuba<sup>1</sup>, Hideo Matsuno<sup>1</sup>, Masahiro Sakuma<sup>1</sup> and Yasuhiro Komatsu<sup>2</sup><sup>1</sup>Kanazawa Medical University, Department of Fundamental Research for CAM, Uchinada, Ishikawa prefecture and <sup>2</sup>Sun R&D Institute for Natural Medicines Co, Inc., Tokyo, Japan

*Phellinus linteus* is a fungus distributed throughout Japan, Korea and China. Boiled water-soluble extracts from *P. linteus* (PLW) have shown anti-tumor and immunomodulatory properties in experiments done by intraperitoneal treatment, or in *in vitro* cell cultures. This is the first investigation on how oral administration of PLW influences immune responses. Here, we established immunodeficient mice by mitomycin C (MMC) and then researched how PLW influenced plaque-forming cell (PFC) production and populations of cytokine [interferon- $\gamma$  (IFN $\gamma$ -) and interleukin-4 (IL-4)]-producing T lymphocytes. PLW samples were administered orally for 19 days (1, 2 or 4 g/kg/day). PFC assay was followed using Jerne's method. IFN- and IL-4-producing T lymphocyte populations were measured by flow-activated cell sorter (FACS). These assays were conducted the day after the last oral administration. MMC groups were given MMC (1 mg/kg/day) intraperitoneally for 6 days with PLW administration. The number of PFC per  $10^6$  spleen cells increased significantly in the PLW (2 g/kg/day) group when compared with the MMC-control ( $P < 0.05$ ) while populations of IFN $\gamma$ - and IL-4-producing T lymphocytes decreased by MMC treatment. However, the PLW group tended to increase more than the MMC-control. Our results indicated that PLW augments the immune response of the spleen in MMC-induced immunodeficient mice.

**Keywords:** immune response – mitomycin C – *Phellinus linteus***Introduction**

In recent years, natural foods have become a vital part of complementary and alternative medicine. Natural products that show anti-tumor activity have been gaining popularity among those faced with the deleterious side effects of treatment using chemotherapeutic drugs or synthetic compounds. In particular, a variety of mushrooms are immune potentiators, and polysaccharides and peptides with anti-tumor activity have been isolated from mushrooms (1) such as black mushroom shiitake, and *Agaricus blazei* Murill (2–5). Among these, *Phellinus linteus* has often been reported for its anti-tumor activity (6–13).

Distributed in Japan, Korea and China as an aqueous extract, *P. linteus* is a traditional Kampo medicine for diarrhea. Its major compounds are polysaccharides, aminoacids,  $\gamma$ -aminobutyric acid, vitamins and sugar. Polysaccharides and proteoglycan isolated from *P. linteus* exhibited cytotoxic action on tumor cells (9) and induced functional maturation of murine dendritic cells (10,11). The aqueous extract of *P. linteus* (PLW) inhibited IgE-dependent mouse triphasic cutaneous reactions (12), and stimulated antibody production (13). These studies, however, were done by intraperitoneal treatment, or in *in vitro* cell culture system, and did not investigate the antibody response to oral administration, which is a much more convenient mode of treatment.

It is unclear how PLW activates the immune system. Controlled by cytokine-producing T lymphocytes, B lymphocytes appear to play an important role in the

For reprints and all correspondence: Shintaro Matsuba, Department of Fundamental Research for CAM, Kanazawa Medical University, Kahoku-Gun, Uchinada, 920-0293, Japan. Tel: 076-286-2211, EXT3923; Fax: 076-286-2841; E-mail: matsuba@kanazawa-med.ac.jp

© 2007 The Author(s).

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/2.0/uk/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

immune response when it is inhibited by overwork, stress, chemotherapeutic drugs and radiotherapy (14). Immunodeficiency caused by anti-tumor drugs such as mitomycin C (MMC) poses a serious problem for cancer patients. MMC has strong anti-tumor activity, but also restricts bone marrow activity (15–17). Therefore, patients treated with MMC often develop a serious immunodeficiency and it is for this condition that we considered the potential of PLW. Since PLW has modulated the immune response of Th1/Th2 cytokine secretion in murine splenocytes (18,19) and Mossman proposed that Th1/Th2 balance is associated with the immune system (20–22), PLW treatment offered promise as a treatment for this immunodeficient condition caused by MMC. We have already established the mechanism of oral administration of the mushroom by investigating how oral intake of Kampo medicine and fungus augmented various immune activities (23–27). We became convinced that PLW could be used for this condition and established an immunodeficient mouse model using MMC to investigate PLW's influence on the immune system.

## Methods

### Mice

Female C57BL/6J strain mice 8 weeks of age obtained from Japan SLC (Hamamatsu, Japan), were bred and treated in conformity with the guidelines for animal experiments at Kanazawa Medical University. They were housed for 1 week with a 12h light–dark cycle in a temperature and humidity controlled room, and were given free access to food and water. After adaptation to the lighting conditions for 1 week, healthy mice were chosen for the investigation.

### Preparation of *P. linteus*

Mycelium of *P. linteus* was a gift from Iwata Chemical Co., LTD. (Iwata, Japan). The boiled water extract (abbreviated as PLW) was prepared as follows: 1 kg of the dried Mycelium was refluxed with 10l of water for 10h, and the aqueous extract was freeze-dried (375 g, 37.5%). It was found to contain 6.4% protein, 83.2% polysaccharide (4.4% of  $\beta$ -glucan) and under 0.1% fat.

### Preparation of Mitomycin C-Induced Immunodeficient Mice

Female mice 8 weeks of age were used. Mice in MMC-treated groups received intraperitoneal injections of MMC 1 mg/kg/day of their body weight for 6 days (28,29). According to a fixed rule, MMC medicine (obtained from Kyowa Hakko Kogyo Co., Ltd, Tokyo, Japan), was dissolved in distilled water. The control group was injected with an equivalent volume of saline. Weighing of the spleen and assay of its plaque-forming cells (PFC) were done 1, 2, 3 and 4 weeks after MMC

treatment. The population of CD19-positive cells in the spleen was measured 1 week after treatment by flow cytometry.

### Immunopotentiating Activity of PLW in Immunodeficient Mice

The schedule is shown in Fig. 1. Mice were divided into five groups (Control, MMC-control, MMC-PLW1, MMC-PLW2 and MMC-PLW3). Control and MMC-control groups were given distilled water, and MMC-PLW groups were administered orally 1, 2 or 4 g/kg/day of PLW for 19 days. MMC-groups were given MMC (1 mg/kg/day) intraperitoneally for 6 days with PLW administration (28–30). The day after the last administration, we measured weight change in the spleen, researched PFC production and the population of cytokine [interferon- $\gamma$  (IFN $\gamma$ ) and interleukin-4 (IL-4)]-producing cells in the spleen.

### PFC Production in Normal Mice Measured after 19 days of PLW

Female C57BL/6J mice were divided into four groups (Control, PLW1, PLW2 and PLW3). The control group was given distilled water and PLW groups were orally administered 1, 2 or 4 g/kg/day of PLW for 19 days. The day after PLW treatments, we investigated change in spleen weight and PFC production of spleen cells.

### Assay of Plaque-Forming Cells

Sheep red blood cells (SRBC), used as antigens and obtained from Japan Biomaterial Center (Tokyo, Japan), were washed three times with saline. Mice received i.v. injections of  $1 \times 10^8$  SRBC. After 4 days, spleen cells from these mice were centrifuged twice at 490g for 5 min and suspended in 10 ml of 10% fetal calf serum, Roswell Park Memorial Institute (FCS-RPMI) 1640 medium (sigma, USA). Spleen cells were counted by Tulk test, a standard method. The number of PFC against SRBC antigen was determined by the method of Jerne *et al.* (31). Briefly, 100  $\mu$ l aliquots of the spleen cell suspension





Figure 1. The experimental schedule of PLW on immune response.



**Figure 2.** Recovered period from immunodeficient condition by Mitomycin C treatments (i.p., 1 mg/kg/day, 6 days) on the weight of spleen (mg) and the number of PFC per  $10^6$  spleen cells in normal mice. Each value represents the mean  $\pm$  SD ( $n=7$ ); \*\* $P<0.005$  versus control.

were mixed with 800  $\mu$ l of Eagle's MEM agar, 100  $\mu$ l of 8% SRBC and 0.5% DEAE-Dextran (Pharmacia, Sweden) in the final volume of 1.1 ml. These samples were incubated (37°C, 5% CO<sub>2</sub>, 2 h) on the bottom layer (Eagle's minimum essential medium MEM agar). Guinea pig serum, isolated from the blood of the Hartley guinea pig, was added to the samples and incubated for 1 h. Hemolytic plaque of SRBC was counted by the naked eye.

### Analysis of Surface Antigens

The expression of surface antigens and cytokines in spleen cells was determined by direct immunofluorescence (32,33). Spleen cells ( $1 \times 10^6$  cells/100  $\mu$ l) were stained with final 0.5  $\mu$ g of fluorescein-isothiocyanate (FITC)-conjugated or phycoerythrin (PE)-conjugated monoclonal antibody (mAb) at room temperature for 0.5 h. The FITC-conjugated anti-CD3 mAb, the PE-conjugated anti-IFN $\gamma$  and -IL-4 mAb were obtained from Becton Dickinson. After incubation, these cells were centrifuged twice at 490g for 5 min with 1 ml of phosphate-based solution (PBS) and suspended in 0.5 ml of PBS containing 100  $\mu$ g/ml CaCl<sub>2</sub>/MgCl<sub>2</sub>, 0.01% sodium azide and 1% FCS, and then analyzed using a FACScan flow cytometer (Becton Dickinson, USA).

### Statistical Analysis

All values expressed as means  $\pm$  S.D. Data were statistically analyzed by one-way analysis of variance (ANOVA) with the level of significance set at  $P<0.05$ . Critical differences between means were evaluated by Dunnett's multiple comparison test set at  $P<0.05$ .

**Table 1.** The population of CD19-positive cell 1 week after MMC treatment in spleen cells

	CD19-positive cells (%)
Control	50.5 $\pm$ 2.5
MMC-1w	47.1 $\pm$ 1.5

Each value represents the mean  $\pm$  SD ( $n=7$ ).


## Results

### Antibody Production after Mitomycin C Treatment

In researching augmentation of the immune response to PLW administration in immunodeficient mice, we investigated the recovery period from MMC-initiated immunodeficiency. Results showed that PFC were not produced 1 week after the last treatment. However, production gradually recovered after 2 weeks (Fig. 2). The numbers of PFC per  $10^6$  spleen cells in each period were  $88 \pm 27$  (2 weeks),  $261 \pm 145$  (3 weeks),  $371 \pm 144$  (4 weeks), showing significant differences at 1 and 2 weeks against the control ( $P<0.005$ ). Spleen weight at 1 week was lower than that of the control ( $P<0.005$ ). There was no significant difference between the populations of CD19-positive cells in the spleen (Table 1), suggesting that MMC treatment only slightly altered the CD19-positive cell population. Since recovery from immunodeficiency began 2 weeks after the last MMC treatment, we decided to assay PFC and flow-activated cell sorter (FACS) at that time.

### Immunomodulating Activity of PLW in Immunodeficient Mice

We examined how PLW influenced splenic weight and PFC numbers per  $10^6$  spleen cells in immunodeficient



**Figure 3.** Effects of PLW treatments for 19 days on the weight of spleen (mg) and the number of PFC in mitomycin C-induced immunodeficient mice. Each value represents the mean  $\pm$  SD ( $n=7$ ); \* $P < 0.05$  versus MMC-control.

mice. There was no significant difference among the spleen weights of each group, as shown in Fig. 3. The number of PFC per  $10^6$  spleen cells was  $502 \pm 93$  in the control,  $118 \pm 80$  (MMC-control),  $184 \pm 49$  (MMC-PLW1),  $279 \pm 69$  (MMC-PLW2) and  $183 \pm 79$  (MMC-PLW3), showing a significant difference between the MMC-control and MMC-PLW2 ( $P < 0.05$ ) and suggesting that PLW augments antibody production in immunodeficient mice.

### Cytokine (IFN $\gamma$ and IL-4)-Producing T Lymphocytes in Spleen Cells

FACS data is shown in Table 2. The population of IFN $\gamma$ - and IL-4- producing T lymphocytes decreased by MMC treatment while IFN $\gamma$ - and IL-4-positive cells of PLW administration groups tended to increase (without significance) compared with the MMC-control. The population of CD3-positive cells was unchanged.

### PLW Administration Did Not Increase Antibody Production in Normal Mice

Although PLW administration has shown immunopotentiating activity for immunodeficient conditions, its influence on normal conditions is unclear. Our results on normal mice showed that the number of PFC per  $10^6$  spleen cells were  $350 \pm 53$  in the control,  $448 \pm 78$  in PLW1,  $446 \pm 131$  in PLW2 and  $383 \pm 101$  in PLW3. No significant differences were observed among any of the groups, as shown in Fig. 4. PLW treatments for 19 days did not increase either antibody production or spleen weight.


**Table 2.** Effect of PLW oral administration for 19 days on T lymphocyte subsets ratio in Mitomycin C-induced immunodeficient mice

	CD3	IFN $\gamma$	IL-4
Control	46.39 $\pm$ 1.94	4.50 $\pm$ 0.28	0.76 $\pm$ 0.04
MMC-control	44.59 $\pm$ 1.45	1.75 $\pm$ 0.35	0.47 $\pm$ 0.15
MMC-PLW1	47.24 $\pm$ 6.93	2.11 $\pm$ 0.47	0.78 $\pm$ 0.29
MMC-PLW2	44.90 $\pm$ 1.84	2.74 $\pm$ 1.42	1.38 $\pm$ 0.75
MMC-PLW3	47.81 $\pm$ 0.60	2.22 $\pm$ 0.11	2.69 $\pm$ 0.75

Each value represents the mean  $\pm$  SD ( $n=4$ ).

### Discussion

As mentioned above, immunodeficiency is a serious side effect of chemotherapeutic drugs. We considered that this condition would be more receptive to PLW treatments than normal conditions and normal mice appear to be only slightly affected by PLW. Firstly, we made an immunodeficient mouse model by MMC treatment. We selected PFC assay in splenocytes as an index of immune activity. This is a typical method to directly observe antibody secreting cells. PFC production was completely inhibited by MMC treatments (1 mg/kg/day) for 6 days. The condition continued for 1 week, and gradually recovered without treatment. The spleen weights of the MMC-1w group were considerably lower than the control, and recovered completely after 2 weeks. However, there was no significant difference in CD19 antigen positive cells between MMC-1w and the control. This antigen exists on the cell surface membrane of non-activated B lymphocytes (34) and the treatment did not alter production suggesting that the maturation of lymphocytes was being inhibited and would not change during the treatment period.



**Figure 4.** Effect of PLW oral administration for 19 days on the weight of spleen and the number of PFC in normal mice. Each value represents the mean  $\pm$  SD ( $n=8$ ).

To analyze how PLW administration altered immune responses, we decided to assay 2 weeks after the last MMC treatment. At this time, PFC production is beginning to recover and the condition of the mouse is closest to that of the immunodeficient patient. The number of PFC per  $10^6$  spleen cells against SRBC antigen was lower in the MMC-treated groups than in the controls. However, the numbers almost doubled in PLW-treated groups when compared with MMC-controls, while there were no differences in spleen weights of the two groups. The increase was not dose-dependent with the most effective dosage being PLW 2 g/kg. The production of the 4 g/kg group was lower than that of the 2 g/kg group.

Since PLW administration enhanced antibody production (mainly IgM), it was possible that IgG would be elevated if the isotype switched from IgM to IgG in the immunoglobulin. In spleens harvested from mice 4 days after immunization, the population of IFN $\gamma$  or IL-4 antigen positive cells was lower in the MMC-control than the control. However, these populations tended to recover with PLW administration. IFN $\gamma$  antigens are present on IFN $\gamma$ -producing T lymphocytes and IL-4 antigens are present on IL-4-producing T lymphocytes, while CD3 antigens only exist on the cell surface membrane of T lymphocytes. The production of IL-4 plays a role in B cell differentiation and it has been suggested that the augmentation of antibody response that occurs with PLW results from expansion of IL-4-producing cells. Since IFN $\gamma$  augments tumoricidal activity (35) and induces functional maturation of dendritic cells (10,11), the augmenting effect of PLW may result from expansion of IFN $\gamma$ -producing T lymphocytes, as has been reported in normal mice (18,19).

The destruction of balance in the body leads to immune disease (20–22) and PLW has the ability to change Th1/Th2 balance and thus augment antibody production

in immunodeficient mice. Since PLW augments the immune system, it may be used to prevent various diseases. In correlation, it may be viable for strengthening the immunodeficient condition of cancer patients. However, further investigation of the immunopotentiating activity of PLW compounds is necessary.

## References

1. Lindequist U, Niedermeyer TH, Julich WD. The pharmacological potential of mushrooms. *Evid Based Complement Alternat Med* 2005;2:285–99.
2. Ooi VE, Liu F. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. *Curr Med Chem* 2000;7:715–29.
3. Hamuro J, Rollinghoff M, Wagner H.  $\beta$ (1-3)Glucan-mediated augmentation of alloreactive murine cytotoxic T-lymphocytes *in vivo*. *Cancer Res* 1978;38:3080–5.
4. Mizuno T, Wasa T, Ito H, Suzuki C, Ukai N. Antitumor-active polysaccharides isolated from the fruiting body of *Hericium erinaceum*, an edible and medicinal mushroom called *yamabushitake* or *houtou*. *Biosci Biotechnol Biochem* 1992;56:347–8.
5. Mizuno M, Norimoto M, Minato K, Tsuchida H. Polysaccharide from *Agaricus blazei* stimulate lymphocyte T-cell subsets in mice. *Biosci Biotechnol Biochem* 1998;62:434–7.
6. Li G, Kim DH, Kim TD, Park BJ, Park HD, Park JI, et al. Protein-bound polysaccharide from *Phellinus linteus* induces G2/M phase arrest and apoptosis in SW480 human colon cancer cells. *Cancer Lett* 2004;28;216:175–81.
7. Han SB, Lee CW, Jeon YJ, Hong ND, Yoo ID, Yang KH, et al. The inhibitory effect of polysaccharides isolated from *Phellinus linteus* on tumor growth and metastasis. *Immunopharmacol* 1999; 41:157–64.
8. Shibata Y, Kurita S, Okugi H, Yamanaka H. Dramatic remission of hormone refractory prostate cancer achieved with extract of the mushroom, *Phellinus linteus*. *Urol Int* 2004;73:188–90.
9. Kim GY, Oh YH, Park YM. Acidic polysaccharide isolated from *Phellinus linteus* induces nitric oxide-mediated tumoricidal activity of macrophages through protein tyrosine kinase and protein kinase C. *Biochem Biophys Res Commun* 2003;309:399–407.
10. Kim GY, Han MG, Song YS, Shin BC, Shin YI, Lee HJ, et al. Proteoglycan isolated from *Phellinus linteus* induces toll-like receptors 2- and 4-mediated maturation of murine dendritic cells via activation of ERK, p38, and NF- $\kappa$ B. *Biol Pharm Bull* 2004;27:1656–62.
11. Park SK, Kim GY, Lim JY, Kwak JY, Bae YS, Lee JD, et al. Acidic polysaccharides isolated from *Phellinus linteus* induce phenotypic and functional maturation of murine dendritic cells. *Biochem Biophys Res Commun* 2003;312:449–58.

12. Inagaki N, Shibata T, Itoh T, Suzuki T, Tanaka H, Nakamura T, et al. Inhibition of IgE-dependent mouse triphasic cutaneous reaction by boiling water fraction separated from mycelium of *Phellinus linteus*. *Evid Based Complement Alternat Med* 2005;2:369–74.
13. Song KS, Cho SM, Lee JH, Kim HM, Han SB, Ko KS, et al. B-lymphocyte-stimulating polysaccharide from mushroom. *Phellinus linteus*. *Chem Pharm Bull* 1995;43:2105–8.
14. Edwards AJ, Bacon TH, Elms CA, Verardi R, Felder M, Knight SC. Changes in the population of lymphocyte cells in human peripheral blood following physical exercise. *Clin Exp Immunol* 1984;58:420–7.
15. Ohtake N, Suzuki R, Daikuhara H, Nakai Y. Modulation of lung local immune responses by oral administration of a herbal medicine Sho-saiko-to. *Int J Immunopharmacol* 2000;22:419–30.
16. Sugiura K. Studies in a tumor spectrum. VIII. The effect of mitomycin C on the growth of a variety of mouse, rat, and hamster tumors. *Cancer Res* 1959;19:438–45.
17. Kanamori H, Shima T, Morita C, Hara T. Studies on antitumor activity of mitomycin. *J Antibiotics* 1957;10:120–7.
18. Lim BO, Yamada K, Cho BG, Jeon T, Hwang SG, Park T, et al. Comparative study on the modulation of IgE and cytokine production by *Phellinus linteus* grown on germinated brown Rice, *Phellinus linteus* and germinated brown rice in murine splenocytes. *Biosci Biotechnol Biochem* 2004;68:2391–4.
19. Lim BO, Jeon TI, Hwang SG, Moon JH, Park DK. *Phellinus linteus* grown on germinated brown rice suppresses IgE production by the modulation of Th1/Th2 balance in murine mesenteric lymph node lymphocytes. *Biotechnol Lett* 2005;27:613–7.
20. Street NE, Mosmann TR. Functional diversity of T lymphocytes due to secretion of different cytokine patterns. *FASEB J* 1991;5:171–7.
21. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, CoVman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. *J Immunol* 1986;196:2348–57.
22. Sad S, Mosmann TR. Single IL-2 secreting precursor CD4T cell can develop into either Th1 or Th2 cytokine secretion phenotype. *J Immunol* 1994;153:3514–22.
23. Kohno H, Jyumonji N, Yamaguchi N. An investigation of the immune suppression induced by some Saikosaponin derivatives. *Int J Immunopharmacol* 1988;10:845–50.
24. Miyazawa Y, Murayama T, Ooya N, Wang LF, Tung YC, Yamaguchi N. Immunomodulation by a unicellular green algae (*Chlorella pyrenoidosa*) in tumor-bearing mice. *J Ethnopharmacol* 1988;24:135–46.
25. Li AL, Komatsu Y, Ono Y, Nakatani F, Nakashima K, Yamaguchi N. The effect of herbal medicines on the immunodeficient animals by injecting cancer chemotherapeutic agent-special reference to age related recovery of the function. *Kansenshogaku Zasshi* 1996;70:717–26.
26. Yamaguchi N, Yoshida J, Ren LJ, Chen H, Miyazawa Y, Fujii Y, et al. Augmentation of various immune reactivities of tumor-bearing hosts with an extract of *Cordyceps sinensis*. *Biotherapy* 1990;2:199–205.
27. Shimizu S, Kitada H, Yokota H, Yamakawa J, Murayama T, Sugiyama K, et al. Activation of the alternative complement pathway by *Agaricus blazei* Murill. *Phytomedicine* 2002;9:536–45.
28. Kiyohara H, Matsumoto T, Takemoto N, Kawamura H, Komatsu Y, Yamada H. Effect of oral administration of a pectic polysaccharide fraction from a kampo (Japanese herbal) medicine “juzen-taiho-to” on antibody response of mice. *Planta Med* 1995;61:429–34.
29. Takemoto N, Kiyohara H, Maruyama H, Komatsu Y, Yamada H, Kawamura H. A novel type of B-cell mitogen isolated from juzen-taiho-to (TJ-48), a Japanese traditional medicine. *Int J Immunopharmacol* 1994;16:919–29.
30. Mitsuzumi H, Kusamiya M, Kurimoto T, Yamamoto I. Requirement of cytokines for augmentation of antigen-specific antibody responses by ascorbate in cultured murine T-cell depleted splenocytes. *Jpn J Pharmacol* 1998;78:169–79.
31. Jerne NH, Nordin AA. Plaque formation in agar by single antibody-producing cells. *Science* 1963;140:405.
32. Nicholson WA, Russian DA, Austen KF. Natural killer cells are deficient in the surface expression of the complement regulatory protein, decay accelerating factor(DAF). *J Immunol* 1986;137:1275–9.
33. Wang XX. Effect of physical exercise on leukocyte and lymphocyte subpopulations in human peripheral blood. *Cytometry Res* 1998;8:53–61.
34. Krop I, Shaffer AL, Fearon DT, Schlissel MS. The signaling activity of murine CD19 is regulated during cell development. *J Immunol* 1996;157:48–56.
35. Kim GY, Oh WK, Shin BC, Shin YI, Park YC, Ahn SC, et al. Proteoglycan isolated from *Phellinus linteus* inhibits tumor growth through mechanisms leading to an activation of CD11c+CD8+ DC and type I helper T cell-dominant immune state. *FEBS Lett* 2004;576:391–400.

Received December 6, 2005; accepted January 11, 2007